Fed. Circ. Won't Rehear Ruling That Axed 4 OxyContin Patents

Law360, New York (May 4, 2016, 5:47 PM EDT) -- The Federal Circuit declined Wednesday to review a decision that four patents on Purdue Pharma LP's painkiller OxyContin are invalid, cementing a victory for four generics makers that are planning their own version of the drug.

The court's decision not to grant the request for a rehearing leaves in place a panel's Feb. 1 affirmation of the findings of a New York federal judge, who held the patents were invalid as anticipated or obvious.

U.S. District Judge Sidney H. Stein reached his conclusion following a three-week bench trial in 2014 over Teva Pharmaceuticals USA Inc.'s planned generic of OxyContin. The judge...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!